Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease

Bibliography

• ZHU X, RAINA AK, PERRY G, SMITH MA: Alzheimer’s disease: the two-hit hypothesis. Lancet Neurol. (2004) 3:219-226.
   PubMed Web of Science ®Google Scholar
• DEKOSKY ST: Pathology and pathways of Alzheimer´s disease with an update on new developments in treatment. J. Am. Geriatr. Soc. (2003) 51:314-320.
   PubMed Web of Science ®Google Scholar
• McGEER EG, McGEER P: Clinically tested drugs for Alzheimer´s disease. Expert Opin. Investig. Drugs (2003) 12:1143-1151.
   PubMed Web of Science ®Google Scholar
• CRENSTIL V: The pharmacogenomics of Alzheimer´s disease. Ageing Res. Rev. (2004) 3:153-169.
   PubMed Web of Science ®Google Scholar
• LARNER AJ: Alzheimer’s disease: targets for drug development. Mini. Rev. Med. Chem. (2002) 2:1-9.
   PubMedGoogle Scholar
• CASTRO A, CONDE S, RODRIGUEZ-FRANCO MI, MARTINEZ A: Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer’s disease. Mini. Rev. Med. Chem. (2002) 2:37-50.
   PubMed Web of Science ®Google Scholar
• BULLOCK R: Future directions in the treatment of Alzheimer´s disease. Expert Opin. Investig. Drugs (2004) 13:303-314.
   PubMed Web of Science ®Google Scholar
• SUGAYA K: Posible use of autologous stem cell therapies for Alzheimer´s disease. Curr. Alzh. Res. (2005) 2:367-376.
   PubMedGoogle Scholar
• TARIOT PN, FEDEROFF HJ: Current treatment for Alzheimer´s disease and future prospects. Alzheimer Dis. Assoc. Disord. (2003) 17:105-113.
   PubMed Web of Science ®Google Scholar
• KURZ A: The therapeutical of tacrine. J. Neural. Transm. Suppl. (1998) 54:295-299.
   PubMedGoogle Scholar
• REOSA SA, SHERRIFF S, McSHANE R: Memantine for dementia. Cochrane Database Syst Rev. (2005) 2:CD003154.
   PubMedGoogle Scholar
• LANE RM, KIVIPELTO M, GREIG NH: Acetylcholinesterase and its inhibition in Alzheimer’s disease. Clin. Neuropharmacol. (2004) 27:141-149.
   PubMed Web of Science ®Google Scholar
• THOMPSON S, LANCTOT KL, HERRMANN N: The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opin Drug Saf. (2004) 3:425-440.
   PubMedGoogle Scholar
• JOHANNSEN P: Long-term cholinesterase inhibitor treatment of Alzheimer’s disease. CNS Drugs. (2004) 18:757-768.
   PubMed Web of Science ®Google Scholar
• HEYDOM WE: Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer’s disease. Expert Opin. Investig. Drugs (1997) 6:1527-1535.
   PubMedGoogle Scholar
• WILLIAMS BR, NAZARIANS A, GILL MA: A review of rivastigmine: a reversible cholinesterase inhibitor. Clin. Ther. (2003) 25:1634-1653.
   PubMed Web of Science ®Google Scholar
• RACCHI M, MAZZUCCHELLI M, PORRELLO E, LANNI C, GOVONI S: Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol. Res. (2004) 50:441-451.
   PubMed Web of Science ®Google Scholar
• ESKANDER MF, NAGYKERY NG, LEUNG EY, KHELGHATI B, GEULA C: Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer’s plaques and tangles. Brain Res. (2005) 1060:144-152.
   PubMed Web of Science ®Google Scholar
• ZAROTSKY V, SRAMEK JJ, CUTLER NR: Galantamine hydrobromide: an agent for Alzheimer’s disease. Am. J. Health Syst. Pharm. (2003) 60:446-452.
   PubMed Web of Science ®Google Scholar
• GEERTS H, FINKEL L, CARR R, SPIROS A: Nicotinic receptor modulation: advantanges for succesful Alzheimer´s disease therapy. J. Neural. Transm. Suppl. (2002) 62:203-216.
   PubMedGoogle Scholar
• VALENTINE L, MYOUNG-OK K, HERRLING P: List of drugs in development for neurodegenerative diseases. Neurodegenerative Dis. (2004) 1:269-322.
   PubMedGoogle Scholar
• BLASS JP, CYRUS PA, BIEBER F, GULANSKI B: Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer´s disease. Alz. Dis. Assoc. Dis. (2000) 24:39-45.
   Web of Science ®Google Scholar
• BIRKS J, WILCOCK GG: Velnacrine for Alzheimer’s disease. Cochrane Database Syst Rev. (2004) 2:CD004748.
   PubMedGoogle Scholar
• GIACOBINI E: Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol. Res. (2004) 50:433-440.
   PubMed Web of Science ®Google Scholar
• QUAY S: Second annual panel discussion on Alzheimer’s disease hosted by Cold Spring Harbor Laboratory, Mayo, USA (2002).
   Google Scholar
• KAMAL MA, GREIG NH, ALHOMIDA AS, AL-JAFARI AA: Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. Biochem. Pharmacol. (2000) 60:561-570.
   PubMed Web of Science ®Google Scholar
• ZANGARA A: The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer´s disease. Pharmacol. Biochem. Behav. (2003) 75:675-686.
   PubMed Web of Science ®Google Scholar
• BAI DL, TANG XC, HE XC: Huperzine A, a potential therapeutic agent for the treatment Alzheimer´s disease. Curr. Med. Chem. (2000) 7:355-374.
   PubMed Web of Science ®Google Scholar
• JING G, LUO X, HE X, JIANG H, ZHANG H, BAI D: Synthesis and docking studies of alkylene-linked dimmers of (-)-huperzine A. Arzneimittelforschung (2003) 53:753-757.
   PubMed Web of Science ®Google Scholar
• LI C, DU F, YU C et al.: A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. (2004) 18:651-656.
   PubMed Web of Science ®Google Scholar
• MA X, GANG RG; The lycopodium alkaloids. Nat. Prod. Rep. (2004) 21:752-772.
   PubMed Web of Science ®Google Scholar
• KOGEN H, TODA N, TAGO K et al.: Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimer´s disease. Org. Lett. (2002) 4:3359-3362.
   PubMed Web of Science ®Google Scholar
• TODA N, TAGO K, MARUMOTO S et al.: A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer´s disease. Bioorg. Med. Chem. (2003) 11:4389-4415.
   PubMed Web of Science ®Google Scholar
• ABE Y, AOYAGI A, HARA T et al.: Pharmacological characterization of RS-1259, an orally dual inhibitor of acetylcholinesterse and serotonin transporter, in rodents: posible treatment of Alzheimer´s disease. J. Pharmacol. Sci. (2003) 93:95-105.
   PubMed Web of Science ®Google Scholar
• CONTRERAS JM, RIVAL YM, CHAYER S, BOURGUIGNON JJ, WERMUTH CG: Aminopyridazines as cetylcholinesterase inhibitors. J. Med. Chem. (1999) 42:730-741.
   PubMed Web of Science ®Google Scholar
• EDWARDS JG, DINAN TG, WALLER DG, GREENTREE SG: Double-blind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline. Br. J. Clin. Pharmacol. (1996) 42:491-498.
   PubMed Web of Science ®Google Scholar
• PIAO Y, MINESHITA S, KUROIWA T, KOIKE Y: Prevention of minaprine of ischemic neuronal damage and memory impairment in Mongolian gerbils. Nihon Shinkei Seishin Yakurigaku Zasshi (1995) 15:157-163.
   PubMedGoogle Scholar
• SANSONE M, BATTAGLIA M, VETULANI J: Minaprine, but not oxiracetam, prevents desipramine-induced impairment of avoidance learning in mice. Pol. J. Pharmacol. (1995) 47:69-73.
   PubMedGoogle Scholar
• CAMPS P, El-ACHAB M, GORBIG DM et al.: Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer’s disease. J. Med. Chem. (1999) 42:3227-3242.
   PubMed Web of Science ®Google Scholar
• CAMPS P, CUSACK B, MALLENDER WD et al.: Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for the treatment of Azlheimer´s disease. Mol. Pharmacol. (2000) 57:409-417.
   PubMed Web of Science ®Google Scholar
• ROS E, ALEU J, GOMEZ-ARANDA I et al.: The pharmacology of novel acetylcholinesterase inhibitors, (+/-)-huprines Y and X, on Torpedo electric organ. Eur. J. Pharmacol (2001) 421:77-84.
   PubMed Web of Science ®Google Scholar
• DVIR H, WONG DM, HAREL M et al.: 3D structure of Torpedo Californica acetylcholinesterase complexed with huprine X at 2.1 Å resolution: kinetic and molecular dynamic correlates. Biochemestry (2002) 42:2970-2980.
   Google Scholar
• ROMAN, VIVAS N, BADIA A, CLOS MV: Interaction of a new potent anticholinesterasic compound (+/-)huprine X with muscarinic receptors in rat brain. Neurosci. Lett. (2002) 325:103-106.
   PubMed Web of Science ®Google Scholar
• ALCALA MM, MADERUELO A, VIVAS N et al.: Effects of (+/-)-huprine Y and (+/-)-huprine Z, two new anticholinesterasic dugs, on muscarinic receptors. Neurosci. Lett. (2005) 379:106-109.
   PubMed Web of Science ®Google Scholar
• CANUDAS AM, PUBILL D, SUREDA FX et al.: Neuroprotective effects of (+/-)-huprine Y on in vitro and in vivo models of excitoxicity damage. Exp. Neurol. (2003) 180:123-130.
   PubMed Web of Science ®Google Scholar
• JORDA EG, VERDAGUER E, JIMENEZ A et al.: (+/-)-Huprine Y, (+/-)-huprine A and tacrine do not show neuroprotective properties in a apoptotic model of neuronal cytoskeletol alteration. J. Alzheimer Dis. (2004) 6:577-583.
   PubMed Web of Science ®Google Scholar
• WEINSTOCK M, GORODETSKY E, POLTYREV T, GROSS A, SAGI Y, YOUDIM M: A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry. (2003) 27:555-561.
   PubMed Web of Science ®Google Scholar
• YOUDIM MB, AMIT T, BAR-AM O, WEINSTOCK M, YOGEV-FALACH M: Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. Ann. NY Acad. Sci. (2003) 993:378-86.
   PubMed Web of Science ®Google Scholar
• SAGI Y, WEINSTOCK M, YOUDIM MB: Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. Neurochem. (2003) 86:290-297.
   PubMed Web of Science ®Google Scholar
• MARUYAMA W, WEINSTOCK M, YOUDIM MB, NAGAI M, NAOI M: Anti-apoptotic action of anti-Alzheimer drug, TV3326 (N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. (2003) 341:233-236.
   PubMed Web of Science ®Google Scholar
• YOUDIM MB, WEINSTOCK M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 (N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate). Cell Mol. Neurobiol. (2001) 21:555-573.
   PubMed Web of Science ®Google Scholar
• BUCCAFUSCO JJ, TERRY AV, GOREN T, BLAUGRUN E: Potential cognitive actions of (n-propargly-(3R)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task. Neuroscience (2003) 119:669-678.
   PubMed Web of Science ®Google Scholar
• WILKINSON D, MURRIA J: Galantamine, a randomized, double-blind, dose comparison in patients with Alzheimer´s disease. Intl. J. Ger. Psychiatry (2001) 16:852-857.
   PubMed Web of Science ®Google Scholar
• LOPEZ-ARRIETA JM, RODRÍGUEZ JL, SANZ F: Efficacy and safety of nicotine in Alzheimer´s disease patients. Cochrane Database Syst. Rev. (2001) 2:CD001749.
   Google Scholar
• SOREQ H, SEIDMAN S: Acetylcholinesterase: new roles for an ols actor. Nat. Rev. Neurosci. (2001) 2:294-302.
   PubMed Web of Science ®Google Scholar
• LUTTMANN E, LINNEMANN E, FELS G: Galantamine as bis-functional ligand for the acetylcholinesterase. J. Mol. Model. (2002) 8:208-216.
   PubMed Web of Science ®Google Scholar
• NICOLET Y, LOCKRIDGE O, MASSON P, FONTECILLA-CAMPS JC, NACHON F: Crystal structure of human butyrylcholinestersae and of its complexes with substrates and products. J. Biol. Chem. (2003) 278:41141-41147.
   PubMed Web of Science ®Google Scholar
• ISOMA K, ISHIKAWA M, OHTA M et al.: Effects of T-82, a new quinoline derivative, on cholinesterase activity and extracellular acetylcholine concentration in brain. Jpn. J. Pharmacol. (2002) 88:206-212.
   PubMedGoogle Scholar
• ISOAME K, MORIMOTO S, HASEGAWA H, MORITA K, KAMEI J: Effects of T-82, a novel acetylcholinesterase inhibitor, on impaired learning and memory in passive avoidance task in rats. Eur. J. Pharmacol. (2003) 465:97-103.
   PubMed Web of Science ®Google Scholar
• JHEE SS, FABBRI L, PICCINO A et al.: First clinical evaluation of ganstigmine in patients with probable Alzheimer’s disease. Clin. Neuropharmacol. (2003) 26:164-169.
   PubMed Web of Science ®Google Scholar
• CATINELLI S, PELIZZI N, PUCCINI P et al.: Phase I metabolism of ganstigmine. Rat, dog, monkey and human liver microsomal extracts investigated by liquid chromatography electrospray tandem mass spectrometry. J. Mass Spectrom. (2001) 36:1287-1293.
   PubMed Web of Science ®Google Scholar
• WINDISCH M, HUTTER-PAIER B, JERKOVIC L, IMBIMBO B, VILLETTI G: The protective effect of ganstigmine against amyloid β25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition. Neurosci. Lett. (2003) 341:181-184.
   PubMed Web of Science ®Google Scholar
• MAZZUCCHELLI M, PORRELLO E, VILLETTI G, PIETRA C, GOVONI S, RACCHI M: Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells. J. Neural. Transm. (2003) 110:935-947.
   PubMed Web of Science ®Google Scholar
• CAPSONI S, GIANNOTTA S, STEBEL M et al.: Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice. Am. J. Alzheimers Dis. Other Demen. (2004) 19:153-160.
   PubMedGoogle Scholar
• JOHNSON A: Ganstigmine. Chiesi. Curr. Opin. Investig. Drugs (2003) 4:868-873.
   PubMedGoogle Scholar
• INESTROSA NC, ALVAREZ A, CALDERON F: Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid β-peptide into Alzheimer´s filaments. Mol. Psychiatry (1996) 1:359-361.
   PubMed Web of Science ®Google Scholar
• REES T, HAMMOND PI, SOREQ H, YOUNKIN S, BRIMIJOIN S: Acetylcholinesterase promotes βamyloid plaques in cerebral cortex. Neurobiol. Aging (2003) 24:777-787.
   PubMed Web of Science ®Google Scholar
• SVEDBERG, MOUSAVI, M, BEDNAR I, BOGDANOVIC N, NORDBERG A: Compensatory mechanisms and plasticity in the brain of double transgenic mice with the APP Swedish mutation and overexpressing human acetylcholinesterase. 8th International Montreal/Sringfield Symposium on Advances in Alzheimer Therapy, Montreal, Canada (2004):75A.
   Google Scholar
• CASTRO A, MARTINEZ A: Peripheral and dual binding site acetylcholinesterase inhibitors: implications in the treatment of Alzheimer’s disease. Mini. Rev. Med. Chem. (2001) 1:267-272.
   PubMed Web of Science ®Google Scholar
• DORRONSORO I, CASTRO A, MARTINEZ A: Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease-modifying agents. Expert Opin. Ther. Patents (2003) 13:1725-1732.
   Web of Science ®Google Scholar
• RECANATINI M, VALENTI P: Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer’s disease therapeutics. Curr. Pharm. Des. (2004) 10:3157-3166.
   PubMed Web of Science ®Google Scholar
• BARTOLINI M, BERTUCCI C, CAVRINI V, ANDRISANO V: β-Amyloid aggregation induced by human acetylcholinesterase: inhibiton studies. Biochem. Pharmacol. (2003) 65:407-416.
   PubMed Web of Science ®Google Scholar
• MUÑOZ-RUIZ P, RUBIO L, GARCIA-PALOMERO E et al.: Design, synthesis and biological evaluation of dual binding site acetylcholinesterase inhibitors: New disease-modifying agents for Alzheimer´s disease. J. Med. Chem. (2005) 48(23):7223-7233.
   PubMed Web of Science ®Google Scholar
• VERICAT JA, MUÑOZ P, WINDISH M, HUTTER-PAIER B, MEDINA M, MARTINEZ A: NP0361: a dual AChE inhibitor that interferes with the β-amyloid plaque charge load. 5th Neurobiology of Aging Conference, San Diego, USA (2004).
   Google Scholar
• PIAZZI L, RAMPA A, BISI A, GOBBI S, BELLUTI F, CAVALLI A et al.: 3-(4-Benzyl(methyl)amino]phenyl]-6,7- dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesteresa and acetylcholinesterase-induced b-amyloid aggregation: a dual function lead for Alzheimer´s disease therapy. J. Med. Chem. (2003) 46:2279-2282.
   PubMed Web of Science ®Google Scholar
• PIAZZI L, BARTOLINI M, BELLUTI F et al.: Analogues of the dual acetylcholinesterase inhibitor AP2283: síntesis and SAR. Drugs Future (2004) 29(Suppl.A):164.
   Google Scholar
• CAVALLI A, BOLOGNESI ML, BARTOLINI M et al.: Memoquin: a new compound to attack Alzheimer’s disease on multiple fronts. 8th International Montreal/Sringfield Symposium on Advances in Alzheimer Therapy, Montreal, Canada (2004):17F.
   Google Scholar
• BROSSI A, PEI XF, GREIG NH: Phenserine, a novel anticholinesterase related to physostigmine: total synthesis, and biological properties. Austr. J. Chem. (1996) 49:171-190.
   Web of Science ®Google Scholar
• GREIG NH, PEI XF, SONCRAT TT, INGRAM DK, BROSSI A: Phenserine and ring C hetero-analogues: drug candidate for the treatment of Alzheimer´s disease. Med. Res. Rev. (1995) 15:3-31.
   PubMed Web of Science ®Google Scholar
• HUANG A, KODANKO JJ, OVERMAN LE: Asymetric síntesis of pyrrolidinoindolines. Application for the practical total synthesis of (-)-phenserine. J. Am. Chem. Soc. (2005) 126:14043-14053.
   Web of Science ®Google Scholar
• SHAW KT, UTSUKI T; ROGERS J et al.: Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. USA (2001) 98:7605-7610.
   PubMed Web of Science ®Google Scholar
• AL-JAFARI AA, KAMAL MA, GREIG NH, ALHOMIDA AS, PERRY ER: Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine. Biochem. Biophys. Res. Commun. (1998) 248:180-185.
   PubMed Web of Science ®Google Scholar
• GREIG NH, DE MICHELI E, HOLLOWAY HW et al.: The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol. Scand. (2000) 102(Suppl. 176):74-84.
   Web of Science ®Google Scholar
• IKARI H, SPANGLER EL, GREIG NH et al.: Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. Neuroreport (1995) 6:481-484.
   PubMed Web of Science ®Google Scholar
• SAMBAMURTI K, TAYLOR S, CHUNG P et al.: Effect of (-) phenserine on the levels of amyloid precursor protein (APP) and amyloid β-peptide in cell culture and transgenic mice expressing human APP. 8th International Montreal-Springfield Symposium on Advances in Alzheimer Therapy, Montreal, Canada (2004).
   Google Scholar
• PATEL N, SPANGLER EL, GREIG NH, YU QS, INGRAM DK, MEYER C: Phenserine, a novel acetylcholinesterase inhibitor, attenuated impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor. Neuro Report (1998) 9:171-176.
   PubMed Web of Science ®Google Scholar
• HARRISON JE, KIRBY L, BAUMER B et al.: A double blind, randomized, placebo-controlled study of (-)-phenserine in Alzheimer´s disease. 8th International Montreal-Springfield Symposium on Advances in Alzheimer Therapy, Montreal, Canada (April 14 – 17 2004) (Poster 361).
   Google Scholar
• GREIG NH, SAMBAMURTI K, QIANG-SHENG Y, BROSSI A, BRUINSMA GB, LAIHIRI DK: An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer´s disease. Curr. Alzh. Res. (2005) 2:281-290.
   PubMedGoogle Scholar
• WINBLAD B: The efficacy of phenserine in the treatment of mild to moderate Alzheimer´s disease. 7th International Conference AD/PD, Sorrento, Italy (2005).
   Google Scholar
• MESULAM MM, GUILLOZET A, SHAW P et al.: Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol. Dis. (2002) 9:88-93.
   PubMed Web of Science ®Google Scholar
• GREIG NH, LAHIRI DK, SAMBAMURTI K: Butyrylcholinestersae: an important new target in Alzheimer´s disease therapy. Int. Psychogeriatr. (2002) 14(Suppl. 1):77-91.
   PubMed Web of Science ®Google Scholar
• LANE RM, POTKIN SG, ENZ A: Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol. (2005) 5:1-24.
   Google Scholar
• YU Q, HOLLOWAY HW, UTSUKI T, BROSSI A, GREIG NH: Synthesisof novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer’s disease. J. Med. Chem. (1999) 42:1855-1861.
   PubMed Web of Science ®Google Scholar
• LAHIRI DK, FARLOW MR, HINTZ N, UTSUKI T, GREIG NH: Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer´s disease. Acta Neurol. Scand. Suppl. (2000) 176:60-67.
   PubMedGoogle Scholar
• WINBLAD B, JELIC V.: Long-term treatment of Alzheimer’s disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis. Assoc. Disord. (2004) 18:(Suppl. 1):S2-S8.
   PubMed Web of Science ®Google Scholar
• WILKINSON DG, FARNCIS PT, SCHWAM E, PAYNE-PARRISH J: Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging (2004) 21:453-478.
   PubMed Web of Science ®Google Scholar
• INESTROSA NC, SAGAL JP, COLOMBRES M: Acetylcholinesterase interaction with Alzheimer amyloid β. Subcell. Biochem. (2005) 38:299-317.
   PubMedGoogle Scholar
• REES TM, BERSON A, SKLAN EH et al.: Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr. Alzheimer Res. (2005) 2:291-300.
   PubMedGoogle Scholar